This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Tarlatamab established a new standard for relapsed SCLC, with improved survival and easier administration, enhancing treatment accessibility. Zanubrutinib demonstrated sustained efficacy in CLL with del(17p), emphasizing the importance of BTK inhibitors in high-risk hematologic malignancies.
Malesker, PharmD, FCCP, FCCM, FASHP, BCPS +1 More Hypertension is widespread and linked to serious health risks, but new treatments for resistant cases target new mechanisms of action. Jansen, PharmD Candidate , Mark A.
Finerenone, a nonsteroidal MRA, shows promise in reducing HF events and atrial fibrillation, offering potential benefits over steroidal MRAs like spironolactone. Barriers to finerenone integration include cost, access, and existing MRA underutilization, with pharmacists crucial in educating prescribers and patients.
Because of their ability to cover a wide array of bacteria, low adverse effect profile, and oral availability, cephalosporins are commonly used in the treatment of outpatient infections. Of note, only first-, second-, and third-generation cephalosporins are available as oral formulations.
Although the use of colony-stimulating factors (CSFs) is well-established in mitigating severe FN, existing literature suggests there is only an approximate 3% difference in FN rates between various CSF agents.
The convenience of once-daily dosing and a rapid IV bolus administration may offer workflow efficiencies in hospital or surgical settings, where minimizing polypharmacy and streamlining medication administration are important goals.
The presentation emphasized early intervention and personalized treatment plans in managing type 2 diabetes, shifting from "treating to failure" to "treating to target." It is not indicated for type 1 diabetes and carries a boxed warning for thyroid C-cell tumors, with unknown risk in humans.
Further research is needed on the clinical impact, treatment longevity, and cost implications of biosimilar use in pediatric IBD. The study found no significant differences in biosimilar use by age, race, or ethnicity, but regional variations existed. SHOW MORE The study found biosimilar initiation rose to nearly 42% from 2016 to 2023.
Understanding and addressing barriers to medication adherence are crucial for effective treatment of psychiatric disorders and improving patient outcomes. Long-acting injectable antipsychotics may improve adherence in homeless populations, but transportation and clinic visit logistics must be considered.
How will RFK Jr’s American dream for vaccines play out? Gilead’s recently approved drug for HIVprevention, Yeztugo (lenacapavir), has the potential to transform the pre-exposure prophylaxis (PrEP) sector in the US, according to market analysts. Reports LOA and PTSR Model - GS-1720 in Human Immunodeficiency Virus (HIV).
Upon sensing dsRNA, the cell effectively halts protein synthesis, thereby preventing the virus from manufacturing the essential proteins required for its own reproduction. 1,2 The researchers believe that compounds that boost the ISR pathway could be effective candidates for antiviral drugs.
The US Food and Drug Administration (FDA) has placed a clinical hold on several of Gilead’s trials evaluating two HIVtreatment candidates, though the rest of the drugmaker’s diverse pipeline remains unaffected. Gilead is considered the leading big pharma in HIVtreatments. Shares in Nasdaq-listed Gilead opened 0.3%
18 years Administration Oral Oral Oral PK/PD MOA: Nirmatrelvir – inhibitor of the SARS-CoV-2 main protease Prevents viral replicationRitonavir is a CYP3A inhibitor included to increase nirmatrelvir plasma levelsRitonavir alone has NO activity against SARS-CoV-2 Time to peak: Nirmatrelvir: 3 hrs & Ritonavir: 3.98 Introduction.
Preface The Journey - About the blog Provisional Registered Pharmacist Training: Hospital or Community Pharmacy - Advice to fresh pharmacy graduates New to Pharmacy - Study the essentials first The End - Summary of thoughts Tools Rx - My personal notes on medicines and supplements + Drug Album Pharmacist Guides - My personal notes for provisional registered (..)
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content